Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer

Cancer Letters
Giandomenico RovielloDaniele Generali

Abstract

Metastatic gastric cancer is a lethal disease characterized by a very short overall survival, underlining a critical need of new therapeutic options. Unfortunately, although several molecular targets have been investigated, only very few recently approved agents, such as trastuzumab in the HER2-positive setting and ramucirumab, led to a clinical improvement in the outcome of metastatic gastric cancer patients. VEGF (vascular endothelial growth factor) is one of the most potent angiogenic factors and is a signalling molecule secreted by many solid tumours. Since high VEGF expression is one of the characteristic features of gastric carcinomas, targeting VEGF is therefore considered as a promising therapeutic strategy for gastric cancer. In the scenario of possible new target therapies with particular regard to angiogenesis, apatinib is a novel receptor tyrosine kinase inhibitor selectively targeting VEGFR-2. It is an orally-bioavailable agent currently being studied in several solid tumour types showing a promising activity in gastric cancer. Due to the recent positive results as a third line of treatment for metastatic gastric cancer patients, apatinib may be an interesting and novel type of targeted treatment for metastatic gas...Continue Reading

References

Jun 5, 2003·Nature Medicine·Napoleone FerraraJennifer LeCouter
Jun 5, 2004·The Oncologist·Napoleone Ferrara
Sep 12, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Federico RojoJosé Baselga
Oct 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tomislav DragovichJames L Abbruzzese
Mar 21, 2007·Cancer Chemotherapy and Pharmacology·R Longo, G Gasparini
Jun 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jane F ApperleyRichard M Stone
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniJanice P Dutcher
Mar 17, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Toshihiko DoiAtsushi Ohtsu
Aug 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alicia F C OkinesIan Chau
Nov 26, 2010·World Journal of Gastroenterology : WJG·Wei LiTian-Shu Liu
Dec 17, 2010·World Journal of Gastrointestinal Oncology·Jong Gwang KimWansik Yu
Jan 29, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Eliza HawkesDavid Cunningham
Jun 13, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y Y JanjigianS-E Al-Batran
Aug 7, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jin LiHao Yu
Oct 12, 2013·World Journal of Gastroenterology : WJG·Ramon Andrade de MelloAntónio Araújo
Mar 25, 2014·Cancer Treatment Reviews·Florian LordickAndrés Cervantes
Aug 1, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
Aug 13, 2014·Nature Reviews. Gastroenterology & Hepatology·Mina Razzak
Dec 30, 2014·Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology·Elisa FontanaDavid Cunningham
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal
Mar 25, 2015·Critical Reviews in Oncology/hematology·Giuseppe AprileGianpiero Fasola
Jun 7, 2015·Cancer Letters·Luigi MaranoAlberto Patriti
Sep 4, 2015·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Giandomenico RovielloFranco Roviello

❮ Previous
Next ❯

Citations

Apr 17, 2016·Critical Reviews in Oncology/hematology·Roberto PetrioliDaniele Generali
Nov 1, 2016·Journal of Cancer Research and Clinical Oncology·Hong-Dou ChenQiu Li
Feb 7, 2017·Cancer Investigation·Giandomenico RovielloDaniele Generali
Mar 9, 2017·Clinical and Experimental Pharmacology & Physiology·Batoul FarranRaquel C Montenegro
Nov 17, 2017·Journal of Experimental & Clinical Cancer Research : CR·Jia-Qi WuMing-Fang He
Mar 1, 2019·Experimental & Molecular Medicine·Zhichao LiaoJilong Yang
Jun 25, 2019·Journal of Biomolecular Structure & Dynamics·Yanmin ZhangHaichun Liu
Dec 21, 2018·Anti-cancer Agents in Medicinal Chemistry·Marina G MoschettaDebora A P de Campos Zuccari
Jun 1, 2018·Oncotarget·Feng LiJilong Yang
Feb 23, 2020·Oncotarget·Raquel Carvalho MontenegroSusanne Müller
Jun 17, 2016·Anti-cancer Drugs·Giandomenico RovielloDaniele Generali
Dec 14, 2018·Journal of Experimental & Clinical Cancer Research : CR·Dan-Hua XuGang Zhao
Dec 14, 2018·Journal of Materials Chemistry. B, Materials for Biology and Medicine·He ZhaoMei Zhang
May 26, 2018·Indian Journal of Cancer·Xiaowu LiSanyuan Sun
Jul 12, 2020·Clinical Hemorheology and Microcirculation·Yongjuan WuWanbi Wang
Jun 5, 2020·OncoTargets and Therapy·Shanshan NieHongwei Lu
Oct 9, 2020·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Beibei SuXianglin Yuan
Jan 1, 2021·Translational Oncology·Ningning LiLin Zhao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Related Papers

Expert Review of Gastroenterology & Hepatology
Kohei Shitara, Atsushi Ohtsu
Biologics : Targets & Therapy
Matthew Mk ChanJohn R Zalcberg
Journal of the National Comprehensive Cancer Network : JNCCN
Amit MahipalRichard Kim
© 2022 Meta ULC. All rights reserved